Blog: ALIMERA SCIENCES INC : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 2.02. Results of Operations and Financial Condition.

On May 9, 2022, Alimera Sciences, Inc. (“Alimera”) issued a press release
regarding its results of operations and financial condition for the first
quarter ended March 31, 2022 as well as a corporate update. On May 9, 2022 at
9:00 A.M. ET, Alimera will host a conference call and a live webcast on the
Investor Relations section of its corporate website at
During the conference call, Alimera’s executives will discuss the company’s
financial results for the first quarter ended March 31, 2022 and provide an
update on corporate developments. The full text of the press release, which
includes information regarding Alimera’s use of a non-GAAP financial measure, is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Various statements made during the conference call and webcast will or may be
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, regarding, among other things, Alimera’s
expectations (i) regarding the continuing positive trend for Alimera’s business
in the U.S. market, (ii) regarding the beneficial effect of Alimera’s marketing
expenditures as they increase engagement with physicians, and (iii) that sales
in its direct markets in Europe will begin recovering in the second quarter of
2022 and contribute to Alimera’s overall growth toward the middle of the year.
Such forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert or
change these expectations, and could cause actual results to differ materially
from those projected in these forward-looking statements. Meaningful factors
that could cause actual results to differ include, but are not limited to,
uncertainties associated with (a) the continued effects of COVID-19 on the
ability or willingness of patients to visit their retina specialists for ILUVIEN
injections, particularly in the EU; (b) governmental orders and policies adopted
by healthcare facilities to address the COVID-19 pandemic, and the duration of
these limitations; (c) the emergence of COVID-19 variants that may increase the
transmissibility of the coronavirus or be more deadly, or both; (d) the success
or failure of the vaccine campaigns in Alimera’s markets; and (e) the other
factors discussed in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections of Alimera’s
Annual Report on Form 10-K for the year ended December 31, 2021, which is on
file with the SEC and available on the SEC’s website at
Additional factors may also be described in those sections of Alimera’s
Quarterly Report on Form 10-Q for the first quarter of 2022, to be filed with
the SEC soon.

In addition to the risks described above and in Alimera’s reports and other
filings with the SEC, other unknown or unpredictable factors also could affect
Alimera’s results. There can be no assurance that the actual results or
developments anticipated by Alimera will be realized or, even if substantially
realized, that they will have the expected consequences to, or effects on,
Alimera. Therefore, no assurance can be given that the outcomes stated in such
forward-looking statements and estimates will be achieved. All forward-looking
statements contained in the conference call and webcast and in the press release
are expressly qualified by the cautionary statements contained or referred to
herein and therein. These forward-looking statements speak only as of the date
of the conference call and webcast and the press release (unless another date is
indicated). Alimera undertakes no obligation, and specifically declines any
obligation, to publicly update or revise any such forward-looking statements,
whether as a result of new information, future events or otherwise.

The information in Item 2.02 of this Current Report on Form 8-K and the press
release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as
expressly set forth by specific reference in such a filing.



Item 7.01. Regulation FD.

The conference call and webcast, and the press release, include or will include
a non-GAAP financial measure, Adjusted EBITDA. A reconciliation of this non-GAAP
financial measure to the comparable measure calculated and presented in
accordance with GAAP is included in Alimera’s press release issued May 9, 2022
and attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 7.01 is being
“furnished” and not “filed” with the SEC for purposes of Section 18 of the
Exchange Act, or otherwise subject to the liabilities under such section.
Furthermore, such information shall not be deemed incorporated by reference in
any filing under the Securities Act, or the Exchange Act, unless specifically
identified as being incorporated therein by reference.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

No.                                        Description
99.1         Press Release of Alimera Sciences, Inc. dated May 9, 2022
104        Cover Page Interactive Data File (embedded within the inline XBRL document)




© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s